ClinicalTrials.gg
CompletedNCT00493116RENeuUpdated Sep 16, 2013

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta

A Phase 4 interventional study of Interferon-beta-1a and methylprednisolone in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2013-09-16.

Sponsored by Biogen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
16th of 21
20 · median 80
Started
2003
with 2 others
Phase 4
13 of 21
none open now
Registered
8th of 21
by date
Lead sponsor
8 of 21
Biogen

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 16th largest by enrollment, is one of 3 that started in 2003, is one of 13 in phase 4, and was the 8th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This study is to find out if Interferon-beta (IFN-beta) can recover its effectiveness after a washout period in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta

Read the detailed description

This is an explorative multi-centre, open label, non-comparative trial investigating whether it is possible to recover IFN-beta efficacy in breakthrough relapsing-remitting multiple sclerosis patients with high titres of neutralizing IFN-beta antibodies.

Prior to enrollment, treated MS subjects must have been on interferon-beta-1a or interferon-beta-1b for a minimum of 12 months and have reduced bioavailability as defined by the relative expression of MxA mRNA/GAPDH.

Subjects will complete a washout period with concurrent methylprednisolone 500mg PO daily for 3 days every month until they become Neutralizing Antibody negative. Subjects will then be challenged with AVONEX 30mcg IM weekly. Bioavailability will be measured every three months to determine return of biological activity. Clinical and MRI parameters, safety and tolerability will be compared to baseline to determine efficacy.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis

Keywords

  • recovery of efficacy
  • MxA protein
  • neutralizing antibodies
  • Multiple sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have been receiving interferon-beta-1a or interferon-beta-1b for a minimum of 12 consecutive months prior to enrollment
  • Relapsing-Remitting Multiple Sclerosis according to Poser or McDonald criteria
  • EDSS score of 6 or less
  • NAB titre >or equal to 20 via CPE assay or >or equal to 100 via MxA Protein assay measured at least 24 hours after last interferon-beta injection on two consecutive tests at least 3 months apart
  • Reduced bioavailability (relative expression of MxA mRNA/GAPDH

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic or anaphylactic reaction to human albumin, to any interferon, Methylprednisolone or to any other component of study drugs
  • systemic illness
  • History of poorly controlled hypertension, diabetes, or osteoporosis
  • History of uncontrolled seizures within 3 months of enrollment
  • History of Depression or suicidal ideation within 3 months of enrollment
  • Serious local infection (abscess or cellulitis) or systemic infection within 8 weeks of study
  • abnormal screening blood tests
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    1

    Drug: Interferon-beta-1a · Drug: methylprednisolone

Interventions

06

What researchers measure

Primary outcomes

  1. return of bioavailability of AVONEX (interferon-beta-1a) as measured by induction of MxA mRNA

    Time frame: screening and every 3 months from month 6 to month 27

Secondary outcomes

  1. Proportion of patients becoming neutralizing antibody negative

    Time frame: screening and every 3 months from month 3 to month 27

  2. proportion of patients becoming neutralizing antibody positive after treatment with AVONEX

    Time frame: at baseline and every three months

  3. proportion of patents relapse free

    Time frame: months 6, 12, 18 and 24

  4. total relapses

    Time frame: 27 months

  5. proportion of patients with an increase in EDSS of 1 point

    Time frame: screening, 3, 9, 15, 21, and 27 months

  6. Brain atrophy and cumulative number of enlarging T2 lesions on MRI

    Time frame: months 0, 12, and 27

07

Study locations

2 sites
  • Coordinating Research Site
    NSW, Australia
  • Research Site
    Hamilton, New Zealand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2007
First posted
Jun 27, 2007
Start
Oct 2003
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Last update
Sep 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00493116
Lead sponsor
Biogen
First posted
Jun 27, 2007
Start date
Oct 2003
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Sep 16, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interferon beta-1a · Methylprednisolone

Start the discussion